TRIAL DETAIL

Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib (PAGIST)

Drug:
Trial Name:
Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib (PAGIST)
NCT#:
Conditions:
Gastrointestinal Stromal Tumor
Status:
Completed
Phase:
2
Start Date 02/01/2012
Age of Trial (yrs) 9.8
Treatment Phase:
Gleevec-resistant
Drug Category:
KIT/PDGFRA inhibitor+ VEGF inhibitor (TKI)
Strategy:
Block KIT + Block blood vessel growth
Trial Type:
Specifically GIST and only GIST
Other Protocol IDs:
SSG XXI
Sponsor:
Scandinavian Sarcoma Group
Patient Contact:
Mikael H Eriksson, MD, PhD +46 46 171000 ext 77507 mikael.eriksson@med.lu.se
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral
Trial Notes:

Trial Links

Trial Results

Drug Information

Votrient.com website
 
Highlights of prescribing info and full text of prescribing information (PDF)
 
Commitment to Access - GSK's patient assistance program for access to drugs
 
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma
 
FDA approves GSK's Votrient for advanced renal cell cancer (GSK website)
 
FDA presentation: Key new drug applicant information
 
Votrient on rxlist.com
 
Pazopanib-induced hyperbilirubinemia (liver problems) is associated with Gilbert's syndrome UGT1A1 polymorphism - Full text article
 
In the Pipeline: Positive Early Results with Pazopanib in Bladder Cancer
 
Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis
 
Pazopanib for the Treatment of Patients with Advanced Renal Cell Carcinoma (full text article, with good discussion of side effects)
 
Help for patients without drug coverage
 
Pazopanib IC50 Table
 
Suppression of the Nitric Oxide Pathway in Metastatic Renal Cell Carcinoma Patients Receiving Vascular Endothelial Growth Factor–Signaling Inhibitors (PDF)
 
Medical News TODAY article - FDA approves GSK's VOTRIENT (TM) for advanced renal cell cancer
 
FDA approves Votrient® for treatment of patients with certain types of advanced soft tissue sarcoma
 
Votrient - Important changes to frequency of liver test monitoring (PDF)
 

Trial Sites

Name
Address
City
State
Zip
Country
Bergen
N-5021
Norway
Oslo
N-0310
Norway
Tromso
N-9038
Norway
Trondheim
N-7006
Norway
Gothenburg
SE-413 45
Sweden
Linkoping
SE-581 85
Sweden
Lund
SE-221 85
Sweden
Stockholm
SE-171 76
Sweden
Umea
90185
Sweden
Uppsala
SE-751 85
Sweden